COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC:

Get the latest research information from NIH: Menu

Turmeric Effect on Reduction of Serum Prolactin and Related Hormonal Change and Adenoma Size in Prolactinoma Patients

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT01344291
Recruitment Status : Unknown
Verified October 2011 by Haleh Rokni Yazdi, Mashhad University of Medical Sciences.
Recruitment status was:  Recruiting
First Posted : April 29, 2011
Last Update Posted : November 1, 2011
Information provided by (Responsible Party):
Haleh Rokni Yazdi, Mashhad University of Medical Sciences

Brief Summary:
Prolactinoma is the most prevalent anterior hypophysis tumor. The principal treatment for this disorder is Dopamine agonist drugs including bromocriptin and Cabergoline. However, 50% of Bromocriptin treated and 17% of Cabergoline treated patients are resistant to these drugs. Curcumin is the main derivative of turmeric ,an old spice which is used frequently in Indian and Iranian cuisine. It has been proved that curcumin can reduce mammotrope cells proliferation and also intracellular hormone production. The purpose of this study is to evaluate the effect of turmeric on prolactinoma patients.

Condition or disease Intervention/treatment Phase
Hyperprolactinoma Drug: Curcumin Phase 1

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 30 participants
Allocation: N/A
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Study Start Date : July 2011
Estimated Primary Completion Date : July 2012
Estimated Study Completion Date : August 2012

Resource links provided by the National Library of Medicine

Drug Information available for: Curcumin

Intervention Details:
  • Drug: Curcumin
    Curcumin is prescribed to new cases of hyperprolactinoma

Primary Outcome Measures :
  1. serum prolactin level [ Time Frame: 2weeks and one month after treatment ]

Secondary Outcome Measures :
  1. change in LH,FSH and estradiol from baseline [ Time Frame: one month ofter treatment ]

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   20 Years to 45 Years   (Adult)
Sexes Eligible for Study:   Female
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • hyperprolactinemia
  • microprolactinoma

Exclusion Criteria:

  • pregnancy
  • macroadenoma
  • neurologic signs due to tumor

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT01344291

Layout table for location contacts
Contact: haleh rokni, proffessore assisstant 00981082976

Layout table for location information
Iran, Islamic Republic of
Mashad University of Medical Sciences Recruiting
Mashad, Khorasan Razavi, Iran, Islamic Republic of
Contact: haleh rokni    00985118012976   
Sponsors and Collaborators
Mashhad University of Medical Sciences
Layout table for additonal information
Responsible Party: Haleh Rokni Yazdi, assisstant professor, Mashhad University of Medical Sciences Identifier: NCT01344291    
Other Study ID Numbers: Turmeric-01
First Posted: April 29, 2011    Key Record Dates
Last Update Posted: November 1, 2011
Last Verified: October 2011
Keywords provided by Haleh Rokni Yazdi, Mashhad University of Medical Sciences:
Additional relevant MeSH terms:
Layout table for MeSH terms
Anti-Inflammatory Agents, Non-Steroidal
Analgesics, Non-Narcotic
Sensory System Agents
Peripheral Nervous System Agents
Physiological Effects of Drugs
Anti-Inflammatory Agents
Antirheumatic Agents
Antineoplastic Agents
Enzyme Inhibitors
Molecular Mechanisms of Pharmacological Action